Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.

Autor:	Cohen D; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: dancohen@tauex.tau.ac.il., Izak M; Magen David Adom, National Blood Services, Ramat Gan, Israel., Stoyanov E; Magen David Adom, National Blood Services, Ramat Gan, Israel., Mandelboim M; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Central Virology Laboratory, Public Health Services, Ministry of Health, Israel., Perlman S; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Amir Y; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Goren S; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Bialik A; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Kliker L; Central Virology Laboratory, Public Health Services, Ministry of Health, Israel., Atari N; Central Virology Laboratory, Public Health Services, Ministry of Health, Israel., Yshai R; Department of Laboratories, Public Health Services, Ministry of Health, Jerusalem, Israel., Zaide Y; American Medical Laboratories, Herzliya, Israel., Marcus H; Israel Institute for Biological Research, Ness Ziona, Israel., Madar-Balakirski N; Israel Institute for Biological Research, Ness Ziona, Israel., Israely T; Israel Institute for Biological Research, Ness Ziona, Israel., Paran N; Israel Institute for Biological Research, Ness Ziona, Israel., Zimhony O; Infectious Diseases Unit, Kaplan Medical Center, Rehovot, Israel the School of Medicine, Hebrew University and Hadassah, Jerusalem, Israel., Shinar E; Magen David Adom, National Blood Services, Ramat Gan, Israel., Maor Y; Infectious Disease Unit, Wolfson Medical Center, Holon, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel., Muhsen K; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2023 Jul; Vol. 132, pp. 72-79. Date of Electronic Publication: 2023 Apr 16.
DOI:	10.1016/j.ijid.2023.04.395
Abstrakt:	Objectives: The predictors of SARS-CoV-2 reinfection are unclear. We examined predictors of reinfection with pre-Omicron and Omicron variants among COVID-19-recovered individuals. Methods: Randomly selected COVID-19-recovered patients (N = 1004) who donated convalescent plasma during 2020 were interviewed between August 2021 and March 2022 regarding COVID-19 vaccination and laboratory-proven reinfection. The sera from 224 (22.3%) participants were tested for antispike (anti-S) immunoglobulin G and neutralizing antibodies. Results: The participants' median age was 31.1 years (78.6% males). The overall reinfection incidence rate was 12.8%; 2.7% versus 21.6% for the pre-Omicron (mostly Delta) versus Omicron variants. Negative associations were found between fever during the first illness and pre-Omicron reinfection: relative risk 0.29 (95% confidence interval 0.09-0.94), high anti-N level at first illness and Omicron reinfection: 0.53 (0.33-0.85), and overall reinfection: 0.56 (0.37-0.84), as well as between subsequent COVID-19 vaccination with the BNT162b2 vaccine and pre-Omicron 0.15 (0.07-0.32), Omicron 0.48 (0.25-0.45), and overall reinfections 0.38 (0.25-0.58). These variables significantly correlated with immunoglobulin G anti-S follow-up levels. High pre-existing anti-S binding and neutralizing antibody levels against the SARS-CoV-2 Wuhan and Alpha strains predicted protection against Omicron reinfections. Conclusion: Strong immune responses after the first COVID-19 infection and subsequent vaccination with the BNT162b2 vaccine provided cross-protection against reinfections with the Delta and Omicron variants. Competing Interests: Declarations of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu